Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International PerspectivePaulo Ferrez Collett‐Solberg, Joachim Woelfle, Geoffrey Ambler et al.|Hormone Research in Paediatrics|2019Cited by 345
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A. Portale, Karl Insogna, Erik A. Imel et al.|Calcified Tissue International|2019Cited by 160
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statementMargaret Cristina da Silva Boguszewski, Gudmundur Johannsson, César Luiz Boguszewski et al.|European Journal of Endocrinology|2022Cited by 111
Epithelial Sodium Channel Is a Key Mediator of Growth Hormone-Induced Sodium Retention in AcromegalyPeter Kamenický, Marc Lombès|Endocrinology|2008Cited by 104
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Erik A. Imel, Anthony A. Portale et al.|RMD Open|2021Cited by 72